Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *  
   Gerberding Julie L.  
   (Last) (First) (Middle)  
   MERCK & CO., INC., 2000 GALLOPING HILL ROAD  
   KENILWORTH, NJ 07033  

2. Issuer Name and Ticker or Trading Symbol  
   Merck & Co., Inc. [ MRK ]  

3. Date of Earliest Transaction (MM/DD/YYYY)  
   2/24/2022  

5. Relationship of Reporting Person(s) to Issuer  
   (Check all applicable)  
   _____ Director  
   _____ 10% Owner  
   X Officer (give title below)  
   _____ Other (specify below)  
   EVP, Chief Patient Officer  

4. If Amendment, Date Original Filed  
   (MM/DD/YYYY)  

6. Individual or Joint/Group Filing  
   (Check Applicable Line)  
   _ Form filed by One Reporting Person  
   _ Form filed by More than One Reporting Person  

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Trans. Date</th>
<th>Trans. Code (Instr. 8)</th>
<th>Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>Amount (A) or (D)</th>
<th>Price (Instr. 4)</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>2/24/2022</td>
<td>A</td>
<td>9550 (1)</td>
<td>A</td>
<td>$73.51</td>
<td>48712.138 (2)</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  

<table>
<thead>
<tr>
<th>Title of Derivate Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Trans. Date</th>
<th>Trans. Code (Instr. 8)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Amount or Number of Shares Underlying Derivative Security (Instr. 3 and 4)</th>
<th>Price of Derivative Security (Instr. 5)</th>
<th>Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
</table>

Explanation of Responses:  
(1) Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.  
(2) Holdings include shares acquired in dividend reinvestment transactions.

Reporting Owners  

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerberding Julie L. MERCK &amp; CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH, NJ 07033</td>
<td>EVP, Chief Patient Officer</td>
</tr>
</tbody>
</table>

Signatures  

/s/ Kelly E. W. Grez as Attorney-in-Fact for Julie L. Gerberding  
2/28/2022  
**Signature of Reporting Person  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).  
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.